Metropolis Healthcare Limited — PPTs, 13-05-2025: Investor Presentation

1. Financial Highlights:

Metropolis Healthcare posted FY25 revenue of ₹1,331 Cr, up 12% YoY, with adjusted EBITDA of ₹325 Cr (+14%) and PAT of ₹161 Cr (+26%), excluding ~₹21 Cr of one-time acquisition and legal expenses. Q4 revenue reached ₹345 Cr (+10%), EBITDA ₹84 Cr (+5%), and PAT ₹45 Cr (+24%). B2C revenue grew 17% to ₹735 Cr, led by wellness services, while B2B rose 12% to ₹477 Cr. Patient volume and test counts rose 8% and 7%, supported by higher revenue per patient (+9%) and per test (+6%). The balance sheet remained solid with total assets of ₹1,867 Cr and equity of ₹1,335 Cr, reflecting recent acquisitions.

2. Strategic Initiatives & Growth Drivers:

Aggressive network expansion added 29 labs and 3,100+ service centers across ~750 towns, including Tier II/III and new states. Metropolis 3.0 strategy focuses on AI-driven digital tools, enhanced customer experience, and specialties like TruHealth and Oncology. Investments in AI-based recommendation engines and personalized health packages complement new genomic and oncology test launches. Plans include growth in allied services, primary healthcare, and strategic bolt-on acquisitions to accelerate market penetration.

3. Business Developments:

The company completed three acquisitions in Q4 with related one-time costs. New test offerings include HPV DNA self-sampling for cervical cancer and AI-enabled prostate cancer diagnostics. Scientific advisory board expanded to 50+ experts; MedTech educational initiatives and AI-powered reporting and clinical engagement further strengthen the advanced diagnostics portfolio.

4. Market Position & Competitive Advantage:

Metropolis is a leading diagnostics chain with a vast test menu (4,000+ tests) and a strong B2C/B2B presence across metros and emerging markets. Its focus on premium wellness, high-value specialty tests, and technology-driven personalization differentiates it. Integrated digital platforms enhance patient and partner engagement, supporting sustained competitive advantage.

5. Investor Implications:

Robust double-digit revenue and profit growth alongside strong network expansion supports positive growth potential. AI and digital investments enhance scalability and customer loyalty, while specialty and wellness segments improve margins. Investors should watch for execution risks around acquisition integration and margin normalization post one-time expenses. Overall, Metropolis offers a solid growth story driven by premiumization and geographic diversification.